New interview released with Daejin Abidoye, Medical Director from Roche-Genentech in the run up to his keynote address at Cancer Vaccines 2016 next month.
"As a Medical Director in Clinical Development, I help oversee the Genitourinary (GU) Malignancies program for our Immuno-Oncology Franchise. Our lead molecule, Atezolizumab, is a humanized engineered monoclonal antibody that selectively targets PD-L1 and has shown clinical activity in various solid tumor malignancies. As the Clinical Lead for Atezolizumab in Urothelial Cancer, I have led the clinical team through the growth of a comprehensive product development program in urothelial cancer, to the recent approval of atezolizumab for metastatic urothelial cancer (mUC) in the United States."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.